Dolor Technologies

Dolor Technologies has developed the SphenoCath®, a single-use medical device for the precise, needle-free delivery of medication to the sphenopalatine foramen (SPF) to achieve a sphenopalatine ganglion (SPG) block. This procedure, used for over a century, is modernized by the device's design to extend over the middle turbinate, pooling medication directly at the target for consistent, fast-acting results. The company operates a direct-to-provider commercial model, offering educational webinars and support to integrate the procedure into clinical practice globally. Dolor Technologies is a private, commercial-stage company positioned in the growing interventional pain management market.

Patented disposable intranasal drug delivery device designed for precise, needle-free administration of medication to the sphenopalatine foramen (SPF) to achieve a sphenopalatine ganglion (SPG) block.

Competition includes traditional, low-tech methods for SPG blocks (cotton-tipped applicators, atomizer sprays) which are inexpensive but imprecise. Potential future competitors include other medical device companies that may develop rival intranasal delivery systems. The SphenoCath® competes on precision, consistency, and procedural ease rather than direct device-to-device competition at this time.